Trial Profile
Connect MM- The Multiple Myeloma Disease Registry
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 12 Dec 2023 Planned End Date changed from 31 Dec 2024 to 15 Aug 2031.
- 15 Jun 2023 Results analyzing treatment patterns and clinical outcomes in patients with MM previously treated with LEN , presented at the 28th Congress of the European Haematology Association
- 01 Feb 2023 Results (n=232) assessing the treatment patterns, overall survival, health-related quality of life and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice, published in the Clinical Lymphoma, Myeloma & Leukemia.